Chronic Pulmonary Hypertension Diagnostic Market SIZE AND SHARE ANALYSIS - GROWTH TRENDS AND FORECASTS (2025-2032)

Chronic Pulmonary Hypertension Diagnostic Market is segmented By Drug Class (Endothelin Receptor Ant...

Chronic Pulmonary Hypertension Diagnostic Market Size

Market Size in USD Bn

CAGR7.3%

Study Period2025-2032
Base Year of Estimation2024
CAGR7.3%
Market ConcentrationHigh
Major PlayersJohnson & Johnson (Actelion Pharmaceuticals), Bayer AG, United Therapeutics Corporation, GlaxoSmithKline plc, Pfizer Inc. and Among Others
*Disclaimer: Major players are listed in no particular order.
*Source: Coherent Market Insights
setting-icon
Want to purchase customized report?
please let us know !

Chronic Pulmonary Hypertension Diagnostic Market Analysis

The chronic pulmonary hypertension diagnostic market is estimated to be valued at USD 8.05 billion in 2025 and is expected to reach USD 13.18 billion by 2032, growing at a compound annual growth rate (CAGR) of 7.3% from 2025 to 2032. The increasing prevalence of chronic pulmonary hypertension globally is driving the need for early and accurate diagnosis of the condition. Rising healthcare expenditure and improved access to diagnostic tests are also fueling the growth of this market.

Chronic Pulmonary Hypertension Diagnostic Market Size